title: Pharmacokinetics of isepamicin.
abstract: Isepamicin is a new aminoglycoside that has activity against many bacteria resistant to other aminoglycosides. The pharmacokinetics of isepamicin have been characterized in neonatal, pediatric, adult, elderly and renally impaired human populations as well as in clinical trials using the techniques of population pharmacokinetics. The pharmacokinetics of isepamicin are uncomplicated and generally similar to those of other aminoglycosides, although there is some evidence that it may have less tissue accumulation. The drug is completely absorbed following intramuscular administration. The drug is not metabolized and unchanged isepamicin accounts for all of the drug substance in plasma and urine. It is completely eliminated via the renal route; consequently dosing in patients with renal insufficiency has to be adjusted according to the degree of renal impairment. The pharmacokinetics of isepamicin are generally linear. Thus peak plasma concentrations and area under the plasma concentration curve (AUC) values are proportional to the administered dose while clearance (1.1-1.3 mL/min/kg), volume of distribution at steady state (0.23-0.29 L/kg) and half-life (2-2.5 h) are independent of dose. There is no significant accumulation of drug in the plasma with once- or twice-daily dosing. The isepamicin plasma concentration curve following a 1 g intravenous dose to healthy volunteers can be best characterized by a tri-exponential curve corresponding to a t1/2 alpha of 0.17 h, a t1/2 beta of 2.1 h, and a gamma-phase of 34 h. The t1/2 beta represents the elimination phase and changes with age and renal functions, while the gamma-phase represents the return of drug to plasma from a deep compartment including binding in renal tissue. The gamma-phase represents less than 3% of the total AUC and does not change with age. Isepamicin readily distributes to extracellular fluid and pulmonary tissue. In conclusion, isepamicin demonstrates predictable linear kinetics and is similar pharmacokinetically to other aminoglycosides. Preliminary indications of decreased tissue accumulation implied from pharmacokinetic and pharmacodynamic characteristics of isepamicin favour once-daily dosing.
authors.affiliation: Department of Pharmacy and Pharmaceutics, Virginia Commonwealth University, Richmond 23298-0533, USA.
authors.forename: W H
authors.initials: WH
authors.lastname: Barr
authors.forename: R
authors.initials: R
authors.lastname: Colucci
authors.forename: E
authors.initials: E
authors.lastname: Radwanski
authors.forename: N
authors.initials: N
authors.lastname: Zampaglione
authors.forename: D
authors.initials: D
authors.lastname: Cutler
authors.forename: C C
authors.initials: CC
authors.lastname: Lin
authors.forename: M
authors.initials: M
authors.lastname: Elliott
authors.forename: M B
authors.initials: MB
authors.lastname: Affrime
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D002240:Carbohydrate Sequence; D002648:Child; D002675:Child, Preschool; D005839:Gentamicins / Q000493:pharmacokinetics; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D008969:Molecular Sequence Data
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; C016927:isepamicin